CVAC - CureVac N.V.
NASDAQ
->
Healthcare
->
Biotechnology
Tübingen,
Germany
Type: Equity
CVAC price evolution
CVAC
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $202.51 | $300.15 | $402.45 | |
| Short term investments | $3.73 | $3.8 | $2.66 | |
| Net receivables | $11.82 | $30.49 | $14.64 | $14.33 |
| Inventory | $0.47 | $0.46 | $26.21 | $24.8 |
| Total current assets | $584.72 | $251.57 | $377.88 | $478.38 |
| Long term investments | ||||
| Property, plant & equipment | $241.45 | $276.25 | $279.02 | $278.63 |
| Goodwill & intangible assets | $26.83 | $31.32 | $28.35 | |
| Total noncurrent assets | $305.26 | $312.55 | $309.87 | |
| Total investments | $3.73 | $3.8 | $2.66 | |
| Total assets | $854.19 | $556.84 | $690.43 | $788.25 |
| Current liabilities | ||||
| Accounts payable | $13.42 | $7.51 | $18.46 | $48.03 |
| Deferred revenue | $84.81 | $86.83 | $92.68 | |
| Short long term debt | $5.07 | $5.09 | $5 | |
| Total current liabilities | $94.35 | $110 | $167.93 | $186.39 |
| Long term debt | $34.9 | $33.96 | $35.55 | $36.82 |
| Total noncurrent liabilities | $70.3 | $75.59 | $84.92 | |
| Total debt | $39.03 | $40.64 | $41.82 | |
| Total liabilities | $129.49 | $180.3 | $243.52 | $271.31 |
| Shareholders' equity | ||||
| Retained earnings | $697.8 | $349.76 | -$1636.53 | -$1565.98 |
| Other shareholder equity | -$0.02 | -$0.15 | -$0.12 | -$0.07 |
| Total shareholder equity | $376.53 | $446.91 | $516.94 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $402.45 | $495.8 | $811.46 | $1322.59 |
| Short term investments | $2.66 | $4.49 | $4.65 | $2.62 |
| Net receivables | $14.33 | $6.29 | $18.5 | $1.01 |
| Inventory | $24.8 | $23.99 | $56.16 | $14.53 |
| Total current assets | $478.38 | $584.03 | $940.02 | $1389.85 |
| Long term investments | ||||
| Property, plant & equipment | $278.63 | $241.7 | $200.39 | $100.59 |
| Goodwill & intangible assets | $28.35 | $31.78 | $13.24 | $14.15 |
| Total noncurrent assets | $309.87 | $276.44 | $218.22 | $121.5 |
| Total investments | $2.66 | $4.49 | $4.65 | $2.62 |
| Total assets | $788.25 | $860.47 | $1158.24 | $1511.36 |
| Current liabilities | ||||
| Accounts payable | $48.03 | $73.46 | $127.7 | $21.68 |
| Deferred revenue | $92.68 | $107.31 | $142.09 | $658.05 |
| Short long term debt | $5 | $4.98 | $3.47 | $3.23 |
| Total current liabilities | $186.39 | $156.22 | $357.73 | $247.62 |
| Long term debt | $36.82 | $37.11 | $25.42 | $52.04 |
| Total noncurrent liabilities | $84.92 | $170.99 | $112.03 | $552.39 |
| Total debt | $41.82 | $42.09 | $28.89 | $55.28 |
| Total liabilities | $271.31 | $327.22 | $469.77 | $800.01 |
| Shareholders' equity | ||||
| Retained earnings | -$1565.98 | -$1305.81 | -$1056.79 | -$645.07 |
| Other shareholder equity | -$0.07 | -$0.14 | -$0.03 | $0.06 |
| Total shareholder equity | $516.94 | $533.25 | $688.48 | $711.35 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $493.9 | $14.44 | $12.37 | $22.57 |
| Cost of revenue | $40.72 | $41.69 | $53.6 | |
| Gross Profit | $471.97 | -$26.29 | -$29.32 | -$31.03 |
| Operating activities | ||||
| Research & development | $31.09 | $27.82 | $33.36 | |
| Selling, general & administrative | $16.93 | $20.07 | $28.39 | |
| Total operating expenses | $104.56 | $47.33 | $44 | $56.99 |
| Operating income | -$73.62 | -$73.32 | -$88.02 | |
| Income from continuing operations | ||||
| EBIT | -$71.09 | -$69.55 | -$90.81 | |
| Income tax expense | $32.53 | $1.3 | $0.67 | $0.17 |
| Interest expense | $2.19 | $0.15 | $0.34 | -$4.33 |
| Net income | ||||
| Net income | $338.04 | -$72.54 | -$70.55 | -$86.65 |
| Income (for common shares) | -$72.54 | -$70.55 | -$86.65 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $53.76 | $67.42 | $102.99 | $48.87 |
| Cost of revenue | $124.37 | $183.99 | $238.19 | $14.17 |
| Gross Profit | -$70.61 | -$116.57 | -$135.21 | $34.7 |
| Operating activities | ||||
| Research & development | $115.72 | $62.55 | $815.91 | $113.81 |
| Selling, general & administrative | $95.67 | $107 | $102.14 | $54.29 |
| Total operating expenses | $203.6 | $132.88 | $277.06 | $144.51 |
| Operating income | -$274.21 | -$249.46 | -$412.26 | -$109.81 |
| Income from continuing operations | ||||
| EBIT | -$257.48 | -$245.45 | -$402.16 | -$107.75 |
| Income tax expense | $0.2 | -$0.13 | -$0.78 | -$0.73 |
| Interest expense | $2.49 | $3.71 | $10.34 | $22.1 |
| Net income | ||||
| Net income | -$260.17 | -$249.03 | -$411.72 | -$129.12 |
| Income (for common shares) | -$260.17 | -$249.03 | -$411.72 | -$129.12 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$72.54 | -$70.55 | -$86.65 | |
| Operating activities | ||||
| Depreciation | $5.13 | $4.87 | $5.99 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.24 | $0.49 | $1.42 | |
| Total cash flows from operations | -$89.11 | -$96.55 | -$43.6 | |
| Investing activities | ||||
| Capital expenditures | -$3.41 | -$5.07 | -$14.14 | |
| Investments | ||||
| Total cash flows from investing | -$15.87 | -$7.49 | -$5.09 | -$14.41 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.04 | $0.1 | -$0.18 | |
| Net borrowings | -$1.26 | -$1.22 | -$1.23 | |
| Total cash flows from financing | -$3.83 | -$1.22 | -$1.12 | -$1.41 |
| Effect of exchange rate | -$0.29 | $402.63 | $0.47 | -$2.27 |
| Change in cash and equivalents | $148.41 | -$97.82 | -$102.77 | -$59.42 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$260.17 | -$249.03 | -$411.72 | -$129.12 |
| Operating activities | ||||
| Depreciation | $23.39 | $23.74 | $15.67 | $10.67 |
| Business acquisitions & disposals | -$0.28 | |||
| Stock-based compensation | $7.7 | $9.19 | $14.96 | $14.24 |
| Total cash flows from operations | -$267.89 | -$286.18 | -$733.13 | $522.4 |
| Investing activities | ||||
| Capital expenditures | -$52.32 | -$88.02 | -$124.22 | -$36.33 |
| Investments | -$1.16 | |||
| Total cash flows from investing | -$55.2 | -$93.5 | -$127.9 | -$45.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $236.09 | $67.39 | $373.15 | $867.72 |
| Net borrowings | -$5.19 | -$4.22 | -$28.18 | -$47.88 |
| Total cash flows from financing | $230.89 | $63.17 | $344.96 | $819.83 |
| Effect of exchange rate | -$1.15 | $0.84 | $4.94 | -$5.05 |
| Change in cash and equivalents | -$92.19 | -$316.5 | -$516.07 | $1296.96 |
News
Fundamentals
| Market cap | $643.85M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 224.34M |
| Revenue | $543.28M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $108.29M |
| Revenue Q/Q | 2.90K% |
| Revenue Y/Y | 1.17K% |
| P/E ratio | 5.95 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.19 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $0.48 |
|---|---|
| ROA | 14.99% |
| ROE | N/A |
| Debt/Equity | 0.52 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.20 |
| Quick ratio | 6.19 |